HTG Overview Video
HTG’s proprietary RNA technologies are designed to help better understand disease and treatment options for patients and to unlock a disruptive approach to drug discovery.
News & Events
WIN Consortium to Launch New Precision Oncology Study, Bank Samples for Blood Biomarker Discovery
The Worldwide Innovative Networking (WIN) Consortium at its annual symposium this week provided an update on its precision oncology clinical trial pipeline.
HTG Molecular Diagnostics to Announce Third Quarter 2017 Financial Results and Host Conference Call on Tuesday, November 7
TUCSON, Ariz., Oct. 20, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced that it will report its financial results for the three and nine months ended September 30, 2017 after the market close on Tuesday, November 7th. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time.
HTG Molecular Diagnostics to Present at the Cantor Fitzgerald Global Healthcare Conference
TUCSON, Ariz., Sept. 25, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced its management will present a corporate overview at the Cantor Fitzgerald Global Healthcare Conference in New York City on Monday, September 25 at 9:45am Eastern Time.
HTG Molecular Diagnostics Receives ISO 13485 Certification for Health Canada CMDCAS Requirements
TUCSON, Ariz., Sept. 18, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that is has successfully completed an audit of its Quality Management System for continued certification to ISO 13485. This certification was issued by a registrar accredited under the Canadian Medical Device Conformity Assessment System (CMDCAS), which is required by Health Canada for the company to market in vitro diagnostic (IVD) products in Canada.
HTG Molecular Diagnostics Provides Regulatory Update for its HTG EdgeSeq ALKPlus Assay
TUCSON, Ariz., Sept. 11, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced that it expects to complete and file the fourth and final module related to the premarket approval application (PMA) submission for its HTG EdgeSeq ALKPlus Assay in the second quarter of 2018. The first three modules of the PMA have already been submitted to the U.S. Food and Drug Administration (FDA) for review.
HTG Molecular Diagnostics to Present at the Rodman & Renshaw 19th Annual Investment Conference
TUCSON, Ariz., Sept. 06, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced its management will present at the Rodman and Renshaw 19th Annual Global Investment Conference in New York City on Monday, September 11, 2017, at 5:00 p.m. Eastern Time.
HTG Molecular Diagnostics’ Technology to be Used in WIN Consortium NSCLC Clinical Trial
TUCSON, Ariz., Aug. 09, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced that its HTG EdgeSeq technology will be used together with Illumina next-generation sequencing (NGS) in a clinical trial conducted by the Worldwide Innovative Networking Consortium (WIN) investigating a novel therapeutic approach using a combination of three targeted therapies for the first line treatment of patients with advanced non-small cell lung cancer (NSCLC).
HTG Molecular Diagnostics Reports Second Quarter 2017 Results
TUCSON, Ariz., Aug. 08, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today reported financial results for the three and six month periods ended June 30, 2017.
HTG Molecular Diagnostics Announces Second Companion Diagnostic Development Project with QIAGEN
TUCSON, Ariz. and VENLO, the Netherlands, July 27, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments, reagents and services for molecular profiling applications today announced the initiation of a second development program under the company’s Master Assay Development, Commercialization and Manufacturing Agreement (“Master Agreement”) with QIAGEN Manchester Limited, a wholly owned subsidiary of QIAGEN N.V. (NASDAQ:QGEN) (Frankfurt Stock Exchange:QIA) (“QIAGEN”). HTG EdgeSeq technology will be used in the program to develop gene expression profiling (“GEP”) assays for use with next-generation sequencing (“NGS”) technology in support of another pharmaceutical company’s therapeutic development and commercialization programs.
HTG Molecular Diagnostics to Present at the Canaccord Genuity Growth Conference
TUCSON, Ariz., July 26, 2017 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced its management will be presenting at the Canaccord Genuity 37th Annual Growth Conference on Thursday, August 10, 2017 in Boston
Page last updated December 15, 2021